HRP20211698T1 - Inhibitori za vezanje creb proteina (cbp) - Google Patents
Inhibitori za vezanje creb proteina (cbp) Download PDFInfo
- Publication number
- HRP20211698T1 HRP20211698T1 HRP20211698TT HRP20211698T HRP20211698T1 HR P20211698 T1 HRP20211698 T1 HR P20211698T1 HR P20211698T T HRP20211698T T HR P20211698TT HR P20211698 T HRP20211698 T HR P20211698T HR P20211698 T1 HRP20211698 T1 HR P20211698T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- image
- compound according
- pharmaceutically acceptable
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| EP19183741.8A EP3587418B1 (en) | 2018-06-29 | 2019-07-01 | Inhibitors of creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211698T1 true HRP20211698T1 (hr) | 2022-02-18 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211698TT HRP20211698T1 (hr) | 2018-06-29 | 2019-07-01 | Inhibitori za vezanje creb proteina (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (OSRAM) |
| EP (1) | EP3998266A1 (OSRAM) |
| JP (4) | JP6781806B2 (OSRAM) |
| KR (2) | KR20250067962A (OSRAM) |
| CN (2) | CN116178369A (OSRAM) |
| AU (3) | AU2019295790B2 (OSRAM) |
| BR (1) | BR112020026783A2 (OSRAM) |
| CA (1) | CA3105099A1 (OSRAM) |
| CY (1) | CY1124762T1 (OSRAM) |
| DK (1) | DK3587418T3 (OSRAM) |
| ES (1) | ES2900105T3 (OSRAM) |
| HR (1) | HRP20211698T1 (OSRAM) |
| HU (1) | HUE056885T2 (OSRAM) |
| IL (3) | IL279734B2 (OSRAM) |
| LT (1) | LT3587418T (OSRAM) |
| MA (1) | MA50675B1 (OSRAM) |
| MX (2) | MX2023013508A (OSRAM) |
| PL (1) | PL3587418T3 (OSRAM) |
| PT (1) | PT3587418T (OSRAM) |
| RS (1) | RS62732B1 (OSRAM) |
| SA (1) | SA520420909B1 (OSRAM) |
| SG (1) | SG11202012767UA (OSRAM) |
| SI (1) | SI3587418T1 (OSRAM) |
| SM (1) | SMT202100636T1 (OSRAM) |
| WO (1) | WO2020006483A1 (OSRAM) |
| ZA (1) | ZA202100509B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019295790B2 (en) * | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
| WO2020190791A1 (en) | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| WO2020190792A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| JP2023532675A (ja) | 2020-06-25 | 2023-07-31 | トルレモ・セラピューティクス・アクチェンゲゼルシャフト | ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ |
| US12472179B2 (en) | 2020-06-25 | 2025-11-18 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| DE60134886D1 (de) | 2000-11-20 | 2008-08-28 | Merck Patent Gmbh | Chirale photoisomerisierbare verbindungen |
| CA2463136A1 (en) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Ship 1 modulators |
| EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (OSRAM) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| JP4790703B2 (ja) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| BRPI0713096A2 (pt) | 2006-05-09 | 2012-10-16 | Hemaquest Pharmaceuticals Inc | métodos para tratar distúrbios sangüìneos |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| IN2014MN02330A (OSRAM) | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| JP5492770B2 (ja) | 2007-06-26 | 2014-05-14 | サノフイ | ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 |
| EP2172453A4 (en) | 2007-06-27 | 2010-12-22 | Taisho Pharmaceutical Co Ltd | CONNECTION WITH 11-β-HSD1 INHIBITING ACTIVITY |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| HUE060249T2 (hu) | 2008-06-16 | 2023-02-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
| EP2412710A4 (en) * | 2009-03-27 | 2012-08-08 | Kowa Co | Fused piperidine compound and pharmaceutical agent comprising same |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CA2758904C (en) | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| US8637499B2 (en) | 2009-05-26 | 2014-01-28 | Exelixis, Inc. | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture |
| WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| AU2010347233B2 (en) | 2010-03-01 | 2015-06-18 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 置換された縮合三環式化合物、組成物およびその医薬用途 |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| DK3071203T3 (da) | 2013-11-18 | 2021-03-15 | Forma Therapeutics Inc | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| EP3242878B1 (en) | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| WO2019055877A1 (en) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| AU2019295790B2 (en) * | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
-
2019
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2024
- 2024-06-09 IL IL313466A patent/IL313466B2/en unknown
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211698T1 (hr) | Inhibitori za vezanje creb proteina (cbp) | |
| HRP20211041T1 (hr) | Anthelmintski depsipeptidni spojevi | |
| HRP20241743T1 (hr) | Derivati kinazolina kao antitumorska sredstva | |
| HRP20161092T1 (hr) | Cdk inhibitori | |
| EP3890786A4 (en) | RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR GENE RELEASE | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| DK3606909T3 (da) | Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid | |
| HRP20230342T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20170154T1 (hr) | Analozi antibakterijskog aminoglikozida | |
| HRP20191524T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme | |
| HRP20211949T1 (hr) | Derivat pirazol primidina i njegove uporabe | |
| HRP20160350T1 (hr) | Heterociklički spojevi i njihove uporabe | |
| HRP20211923T1 (hr) | Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za uporabu u liječenju neurodegenerativnih poremećaja | |
| IL283755B1 (en) | n-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them | |
| HRP20191298T1 (hr) | Arileteri i njihove uporabe | |
| EP3875085A4 (en) | EDARAVON SUSPENSION FOR ORAL ADMINISTRATION | |
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| HRP20211218T1 (hr) | Inhibitori receptora fibroblastnog faktora rasta | |
| HRP20120735T1 (hr) | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora | |
| HRP20220840T1 (hr) | Inhibitori receptora faktora rasta fibroblasta | |
| HRP20210940T1 (hr) | Spoj arilazola i sredstvo za suzbijanje štetočina | |
| MA53927A (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA49253A (fr) | Compositions solides pour administration orale | |
| HRP20241558T1 (hr) | Dvojni inhibitori magl i faah | |
| PH12020550033A1 (en) | Amine or (thio)amide containing lxr modulators |